公开(公告)号：EP1921140A4

公开(公告)日：2009-05-06

申请号：EP06780756

申请日：2006-07-04

申请人： CHEMO SERO THERAPEUT RES INST

发明人： KAMINAKA KAZUYOSHI ,  MAEDA HIROAKI ,  HIRASHIMA MASAKI ,  KAWAMURA RYOICHI ,  MATSUDA JUNICHI ,  KUWANA TAKASHI

IPC分类号： C12N15/09 ,  A01K67/027 ,  C12N5/10

CPC分类号： C12N15/79 ,  A01K2217/05 ,  A01K2227/30 ,  C12N15/102 ,  C12N15/85 ,  C12N15/90 ,  C12N2800/30 ,  C12N2800/90 ,  C12N2820/00

摘要： Disclosed are a mutant transposon vector and a method for introducing a foreign gene into a cell. A mutant transposon vector having a nucleic acid fragment inserted therein, the nucleic acid fragment having the properties (i) and (ii) or the properties (i) to (iii) below; a foreign gene-expressing cell which is prepared by introducing the mutant transposon vector into the chromosomal DNA of an established cell or a cell capable of being individuated and then additionally introducing a foreign gene-expressing cassette into a recombinant system (e.g., Cre-Lox system); a recombinant animal created by using the cell (in the case where the cell capable of being individuated is used); and a method for producing a foreign protein from the cell or the recombinant animal: (i) comprising a 5'-TIR sequence and a 3'-TIR sequence of transposon gene; (ii) having a sequence at which a recombination reaction occurs inserted between at least one set of DR regions of two sets of DR regions present in a 5'-TIR sequence or a 3'-TIR sequence of transposon gene; and (iii) having a restriction recognition site or a foreign gene-expressing cassette inserted between a 5'-TIR sequence and a 3'-TIR sequence of transposon gene.

摘要翻译： 提供了修饰的转座子载体和将外源基因导入细胞的方法。 一种修饰的转座子载体，其中插入具有以下特征（a） - （b）或（a） - （c）的核酸片段; 通过将所述载体导入细胞系或本体细胞的染色体DNA而获得的表达外源基因的细胞，并进一步将外源基因的表达盒导入染色体DNA; 通过使用所述细胞产生的遗传重组的动物（在本体细胞的情况下）; 以及从所述细胞和所述遗传重组动物产生外源蛋白的方法：（a）由转座子基因的5'和3'-TIR序列组成; （b）发生重组反应的序列插入转座子基因的5'-和3-TIR序列中的两个存在的DR区域中的至少任一个之间; （c）在转座子基因的5'和3'-TIR序列之间插入限制酶识别位点或外来基因的表达盒。

公开(公告)号：EP2327419A4

公开(公告)日：2015-12-30

申请号：EP09773249

申请日：2009-05-22

申请人： HISAMITSU PHARMACEUTICAL CO ,  CHEMO SERO THERAPEUT RES INST

发明人： NOZAKI CHIKATERU ,  KAMINAKA KAZUYOSHI ,  MATSUDA JUNICHI ,  TERAHARA TAKAAKI ,  KUWAHARA TETSUJI ,  TOKUMOTO SEIJI

IPC分类号： A61K39/145 ,  A61K9/00 ,  A61K9/70 ,  A61K39/00 ,  A61K39/39 ,  A61K47/10 ,  A61K47/34 ,  A61K47/36 ,  A61L31/00 ,  A61M37/00 ,  A61P31/16

CPC分类号： A61K39/145 ,  A61B17/205 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/541 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/70 ,  A61M37/0015 ,  A61M2037/0046 ,  A61M2037/0061 ,  C12N2760/16134 ,  C12N2760/16234

摘要： The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.

公开(公告)号：EP2348042A4

公开(公告)日：2012-03-28

申请号：EP09820642

申请日：2009-10-16

申请人： CHEMO SERO THERAPEUT RES INST

发明人： MATSUDA JUNICHI ,  KAMINAKA KAZUYOSHI ,  NOZAKI CHIKATERU

IPC分类号： C07K14/435 ,  A61K39/00 ,  A61K48/00 ,  A61P25/28 ,  C12N15/09

CPC分类号： C07K14/4711 ,  A61K39/0007 ,  A61K2039/53

公开(公告)号：EP1566181A4

公开(公告)日：2009-06-17

申请号：EP03812336

申请日：2003-11-28

申请人： CHEMO SERO THERAPEUT RES INST

发明人： KAWAMURA RYOICHI ,  NARUSE TAKESHI ,  HIRASHIMA MASAKI ,  KAMINAKA KAZUYOSHI ,  MATSUDA JUNICHI ,  MAEDA HIROAKI ,  NODA MAMI ,  WADA KEIJI

IPC分类号： A61K38/00 ,  A61K38/17 ,  A61P1/00 ,  A61P3/12 ,  A61P9/00 ,  A61P15/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/06 ,  A61P39/02 ,  A61P43/00 ,  C07K14/47

CPC分类号： A61K38/1709

摘要： It is intended to provide a novel agent for improving neurotransmission failure. In a preferable case, an agent for improving neurotransmission failure which contains, as the major active ingredient(s), a selenocysteine-containing protein typified by selenoprotein P, a C-terminal peptide of this protein or such peptides. This agent is appropriate in improving neurotransmission failure diseases caused by various factors.

摘要翻译： 它旨在提供一种用于改善神经传递失败的新型药剂。 在优选的情况下，作为主要有效成分，含有以硒蛋白P为代表的含硒代半胱氨酸的蛋白质，该蛋白质的C末端肽或这些肽作为改善神经传递障碍的药剂。 该药物适用于改善由各种因素引起的神经传递衰竭疾病。

公开(公告)号：EP2684572A4

公开(公告)日：2014-09-10

申请号：EP12757500

申请日：2012-03-09

申请人： CHEMO SERO THERAPEUT RES INST

发明人： NOZAKI CHIKATERU ,  KAMINAKA KAZUYOSHI ,  MATSUDA JUNICHI

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/145 ,  A61P25/28 ,  A61P31/16 ,  A61P37/04

CPC分类号： A61K39/39 ,  A61K39/0007 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/575 ,  C12N2760/16134 ,  C12N2760/16171

摘要： A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided.

公开(公告)号：EP2471915A4

公开(公告)日：2013-05-01

申请号：EP10811798

申请日：2010-08-23

申请人： CHEMO SERO THERAPEUT RES INST

发明人： KAMINAKA KAZUYOSHI ,  NOZAKI CHIKATERU ,  MATSUDA JUNICHI ,  NISHIYAMA KIYOTO

IPC分类号： C12N15/09 ,  A61K39/145 ,  A61K39/155 ,  A61P31/16 ,  C07K14/005 ,  C07K14/11 ,  C07K16/10 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10

CPC分类号： A61K39/145 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/55505 ,  C07K14/005 ,  C12N2760/16122 ,  C12N2760/16134

摘要： A modified peptide derived from matrix protein 2 (hereinafter also referred to as "M2"), one of surface layer proteins of influenza virus, and a method for utilization of the modified peptide are provided. A peptide (hereinafter also referred to as "M2eC peptide") that is made up by inserting cysteine residue(s) into a peptide (hereinafter also referred to as "M2e") consisting of 23 amino acid residues of from positions No. 2 to No. 24 of M2 in influenza virus type A, a fusion protein consisting of said modified peptide and a polypeptide, an influenza vaccine comprising said modified peptide or said fusion protein as an active ingredient, a device which can be delivered into the body comprising said influenza vaccine, a nucleic acid fragment consisting of a nucleotide sequence encoding the amino acid sequence of said modified peptide or said fusion protein, an expression vector in which said nucleic acid fragment is incorporated, a host in which said expression vector is introduced, and an antibody that has a protective effect against influenza virus.

公开(公告)号：EP2298344A4

公开(公告)日：2013-04-24

申请号：EP09758247

申请日：2009-05-27

申请人： CHEMO SERO THERAPEUT RES INST

发明人： MORIYAMA MAKOTO ,  KAMINAKA KAZUYOSHI ,  MATSUDA JUNICHI ,  NOZAKI CHIKATERU

IPC分类号： A61K39/39 ,  A61P31/04 ,  A61P31/06 ,  A61P31/14 ,  A61P31/16 ,  A61P31/20

CPC分类号： A61K39/00 ,  A61K2039/5252 ,  A61K2039/55588

摘要： A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEW particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method.

公开(公告)号：EP2149584A4

公开(公告)日：2010-07-07

申请号：EP08751882

申请日：2008-04-18

申请人： CHEMO SERO THERAPEUT RES INST

发明人： MATSUDA JUNICHI ,  KAMINAKA KAZUYOSHI ,  NOZAKI CHIKATERU

IPC分类号： C07K14/47 ,  A61K31/711 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61P25/28

CPC分类号： A61K39/0007 ,  A61K31/711 ,  C07K14/4711

摘要： An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid ² peptide that induces an enhanced immune response. An amyloid ² peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid ² peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid ² peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.

摘要翻译： 本发明的目的是提供一种用于增强免疫应答的安全有效的方法和用于预防或治疗阿尔茨海默病的药物，其包含诱导增强的免疫应答的淀粉样蛋白2肽。 具有添加或插入半胱氨酸的淀粉样蛋白2肽或其部分以及使用肽增强免疫应答的方法或使用肽与佐剂一起增强免疫应答的方法。 一种用于预防或治疗阿尔茨海默病的药物，其包含诱导增强的免疫应答的淀粉样蛋白2肽或其部分。 可以具有相同效果的DNA疫苗，其包含编码淀粉样蛋白2肽或其部分的基因，其通过加入或插入半胱氨酸诱导增强的免疫应答。